Delivering phage therapy per os: benefits and barriers

Expert Review of Anti-Infective Therapy

Volumn 15, Issue 2, 2017, Pages 167-179

  Zelasko, Susan ^a   Gorski, Andrzej ^a   Dabrowska, Krystyna ^a  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

Author keywords

Antibiotic resistance; bacterial infection; bacteriophages; enteropathogenic; gastroenteritis; gastrointestinal tract; gut microbiome; phage therapy

Indexed keywords

ADAPTIVE IMMUNITY; CLOSTRIDIUM DIFFICILE INFECTION; ESCHERICHIA COLI INFECTION; GASTROINTESTINAL TRACT; HUMAN; INNATE IMMUNITY; INTESTINE FLORA; NONHUMAN; PHAGE THERAPY; PSEUDOMONAS INFECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SALMONELLOSIS; STAPHYLOCOCCUS INFECTION; VIBRIOSIS; ANIMAL; BACTERIOPHAGE; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; IMMUNOLOGY; MICROBIOLOGY; MULTIDRUG RESISTANCE; ORAL DRUG ADMINISTRATION; PROCEDURES;

ADAPTIVE IMMUNITY; ADMINISTRATION, ORAL; ANIMALS; BACTERIOPHAGES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GASTROINTESTINAL TRACT; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; PHAGE THERAPY;

EID: 85009446383     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1080/14787210.2017.1265447     Document Type: Review

References (129)

1. D’Herelle F., On an invisible microbe antagonistic dysenteric bacilli:brief note by Mr. F. D’Herelle presented by Mr. Roux. Res Microbiol. 2007;158(7):553–554.
2. Chanishvili N. Chapter 1, Phage therapy—history from Twort and d’Herelle through soviet experience to current approaches. In:Małgorzata Ł, Wacław S, editors. Advances in virus research. San Diego:Elsevier Academic Press Inc; 2012;83. p. 3–40.
3. Slopek S, Weber-Dabrowska B, Dabrowski M, et al. Results of bacteriophage treatment of suppurative bacterial infections in the years 1981–1986. Arch Immunol Ther Exp. 1987;35(5):569–583.
4. Ryan EM, Gorman SP, Donnelly RF, et al. Recent advances in bacteriophage therapy:how delivery routes, formulation, concentration and timing influence the success of phage therapy. J Pharm Pharmacol. 2011;63(10):1253–1264.
5. Dabrowska K, Switala-Jelen K, Opolski A, et al. Bacteriophage penetration in vertebrates. J Appl Microbiol. 2005;98(1):7–13.
6. Weber-Dabrowska B, Mulczyk M, Górski A. Bacteriophages as an efficient therapy for antibiotic-resistant septicemia in man. Transplant Proc. 2003;35(4):1385–1386.
7. Brüssow H. Targeting the gut to protect the bladder:oral phage therapy approaches against urinary Escherichia coli infections? Environ Microbiol. 2016;18(7):2084–2088.
8. Majewska J, Beta W, Lecion D, et al. Oral application of T4 phage induces weak antibody production in the gut and in the blood. Viruses. 2015;7(8):4783–4799.• Animal trial demonstrates IgA likely plays a role in the immune system response to orally administered phage T4.
9. Leimbach A, Hacker J, Dobrindt U. E. coli as an all-rounder:the thin line between commensalism and pathogenicity. In:Dobrindt U, Hacker HJ, Svanborg C, editors. Between pathogenicity and commensalism. Berlin:Springer Berlin Heidelberg; 2013. p. 3–32.
10. Liu Y-Y, Wang Y, Walsh TR, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China:a microbiological and molecular biological study. Lancet Infect Dis. 2016;16(2):161–168.
11. Tadesse DA, Zhao S, Tong E, et al. Antimicrobial drug resistance in Escherichia coli from humans and food animals, United States, 1950–2002. Emerging Infect Dis Journal. 2012;18(5):741.
12. Collignon P. Resistant Escherichia coli— we are what we eat. Clin Infect Dis. 2009;49(2):202–204.
13. Lim JY, Yoon JW, Hovde CJ, et al. Overview of Escherichia coli O157:H7and its plasmid O157. J Microbiol Biotechnol. 2010;20(1):5–14.
14. Nassar FJ, Rahal EA, Sabra A, et al. Effects of subinhibitory concentrations of antimicrobial agents on Escherichia coli O157:H7Shiga Toxin Release and Role of the SOS Response. Foodborne Pathog Dis. 2013;10(9):805–812.
15. Angel Villegas N, Baronetti J, Albesa I, et al. Effect of antibiotics on cellular stress generated in Shiga toxin-producing Escherichia coli O157:H7and non-O157 biofilms. Toxicol Vitro. 2015;29(7):1692–1700.
16. Łoś JM, Łoś M, Węgrzyn A, et al. Hydrogen peroxide-mediated induction of the Shiga toxinconverting lambdoid prophage ST2-8624 in Escherichia coli O157:H7. FEMS Immunol Med Microbiol. 2010;58(3):322–329.
17. Tanji Y, Shimada T, Fukudomi H, et al. Therapeutic use of phage cocktail for controlling Escherichia coli O157:H7 in gastrointestinal tract of mice. J Biosci Bioeng. 2005;100(3):280–287.
18. Kudva IT, Jelacic S, Tarr PI, et al. Biocontrol of Escherichia coli O157 with O157-specific bacteriophages. Appl Environ Microbiol. 1999;65(9):3767–3773.
19. Sheng H, Knecht HJ, Kudva IT, et al. Application of bacteriophages to control intestinal Escherichia coli O157:H7levels in ruminants. Appl Environ Microbiol. 2006;72(8):5359–5366.
20. Maura D, Galtier M, Le Bouguénec C, et al. Virulent bacteriophages can target O104:H4Enteroaggregative Escherichia coli in the mouse intestine. Antimicrob Agents Chemother. 2012;56(12):6235–6242.
21. Jaiswal A, Koley H, Mitra S, et al. Comparative analysis of different oral approaches to treat Vibrio cholerae infection in adult mice. Int J Med Microbiol. 2014;304(3–4):422–430.• Comparison of anti-cholera phages to traditional antibiotic therapy demonstrates phages incite fewer inflammatory responses vs. antibiotics and significant bacterial reduction in vivo.
22. Jun JW, Shin TH, Kim JH, et al. Bacteriophage therapy of a Vibrio parahaemolyticus infection caused by a multiple-antibiotic-resistant O3:K6Pandemic clinical strain. J Infect Dis. 2014;210(1):72–78.• Examination of phage pVp-1 shows efficacy in reducing V. parahaemolyticus levels in vivo when delivered orally.
23. Nale JY, Spencer J, Hargreaves KR, et al. Bacteriophage combinations significantly reduce Clostridium difficile growth in vitro and proliferation in vivo. Antimicrob Agents Chemother. 2016;60(2):968–981.• Examination of various phage combinations delivered orally show efficacy in reducing C. difficile levels in vivo.
24. Watanabe R, Matsumoto T, Sano G, et al. Efficacy of bacteriophage therapy against gut-derived sepsis caused by Pseudomonas aeruginosa in mice. Antimicrob Agents Chemother. 2007;51(2):446–452.• Examination of OPT that shows efficacy in reducing GI and systemic P. aeruginosa levels in vivo.
25. Colom J, Cano-Sarabia M, Otero J, et al. Liposome-encapsulated bacteriophages for enhanced oral phage therapy against Salmonella spp. Appl Environ Microbiol. 2015;81(14):4841–4849.• Encapsulation of phages increases their retention in the GI tract and efficacy in reducing Salmonella levels in vivo.
26. Maura D, Morello E, Du Merle L, et al. Intestinal colonization by enteroaggregative Escherichia coli supports long-term bacteriophage replication in mice. Environ Microbiol. 2012;14(8):1844–1854.
27. Jamalludeen N, Johnson RP, Shewen PE, et al. Evaluation of bacteriophages for prevention and treatment of diarrhea due to experimental enterotoxigenic Escherichia coli O149 infection of pigs. Vet Microbiol. 2009;136(1–2):135–141.
28. Smith HW, Huggins MB. Effectiveness of phages in treating experimental Escherichia coli diarrhoea in calves, piglets and lambs. J Gen Microbiol. 1983;129(8):2659–2675.
29. Nguyen TLA, Vieira-Silva S, Liston A, et al. How informative is the mouse for human gut microbiota research? Dis Models Mech. 2015;8(1):1–16.
30. Zhang Q, Widmer G, Tzipori S. A pig model of the human gastrointestinal tract. Gut Microbes. 2013;4(3):193–200.
31. Ruppé E, Lixandru B, Cojocaru R, et al. Relative fecal abundance of extended-spectrum-β-lactamase-producing Escherichia coli strains and their occurrence in urinary tract infections in women. Antimicrob Agents Chemother. 2013;57(9):4512–4517.
32. Galtier M, De Sordi L, Maura D, et al. Bacteriophages to reduce gut carriage of antibiotic resistant uropathogens with low impact on microbiota composition. Environ Microbiol. 2016;18(7):2237–2245.• Gut decolonization using orally administered anti-E. coli phage cocktail to reduce uropathogenic E. coli dissemination.
33. Sarker SA, Sultana S, Reuteler G, et al. Oral phage therapy of acute bacterial diarrhea with two coliphage preparations:a randomized trial in children from Bangladesh. EBioMedicine. 2016;4:124–137.•• Human clinical trial evaluating anti-E. coli phage cocktails shows low efficacy, possibly due to short therapy course and low levels of phage-susceptible target pathogen.
34. Bourdin G, Navarro A, Sarker SA, et al. Coverage of diarrhoea-associated Escherichia coli isolates from different origins with two types of phage cocktails. Microb Biotechnol. 2014;7(2):165–176.
35. Bhowmick TS, Koley H, Das M, et al. Pathogenic potential of vibriophages against an experimental infection with Vibrio cholerae O1 in the RITARD model. Int J Antimicrob Agents. 2009;33(6):569–573.
36. Jaiswal A, Koley H, Ghosh A, et al. Efficacy of cocktail phage therapy in treating Vibrio cholerae infection in rabbit model. Microbes Infect. 2013;15(2):152–156.
37. Nelson EJ, Harris JB, Glenn Morris J, et al. Cholera transmission:the host, pathogen and bacteriophage dynamic. Nat Rev Micro. 2009;7(10):693–702.
38. Qadri F, Wierzba TF, Ali M, et al. Efficacy of a single-dose, inactivated oral cholera vaccine in Bangladesh. New England J Med. 2016;374(18):1723–1732.
39. Garg P, Sinha S, Chakraborty R, et al. Emergence of Fluoroquinolone-Resistant Strains of Vibrio cholerae O1 Biotype El Tor among Hospitalized Patients with Cholera in Calcutta, India. Antimicrob Agents Chemother. 2001;45(5):1605–1606.
40. Thapa Shrestha U, Adhikari N, Maharjan R, et al. Multidrug resistant Vibrio cholerae O1 from clinical and environmental samples in Kathmandu city. BMC Infect Dis. 2015;15:104.
41. Folster JP, Katz L, McCullough A, et al. Multidrug-resistant IncA/C plasmid in Vibrio cholerae from Haiti. Emerg Infect Dis. 2014;20(11):1951–1953.
42. Berthe M, Sandra M, Jean-Jacques M, et al. Antimicrobial drug resistance of Vibrio cholerae democratic Republic of the Congo. Emerging Infect Dis Journal. 2015;21(5):847.
43. Maria S-K, Aleisha R, Jason PF, et al. Drug-resistance mechanisms in Vibrio cholerae O1 outbreak strain, Haiti, 2010. Emerging Infect Dis Journal. 2011;17(11):2151.
44. Letchumanan V, Chan K-G, Pusparajah P, et al. Insights into bacteriophage application in controlling Vibrio species. Front Microbiol. 2016;7(1114) 10.3389/fmicb.2016.01114.
45. Azman AS, Rudolph KE, Cummings DAT, et al. The incubation period of cholera:a systematic review. J Infect. 2013;66(5):432–438.
46. Marcuk LM, Nikiforov VN, Scerbak JF, et al. Clinical studies of the use of bacteriophage in the treatment of cholera. Bull World Health Organ. 1971;45(1):77–83.
47. Kirn TJ, Jude BA, Taylor RK. A colonization factor links Vibrio cholerae environmental survival and human infection. Nature. 2005;438(7069):863–866.
48. Letchumanan V, Pusparajah P, Tan LT-H, et al. Occurrence and antibiotic resistance of Vibrio parahaemolyticus from shellfish in Selangor. Malaysia Front Microbiol. 2015;6:1417.
49. Elmahdi S, DaSilva LV, Parveen S. Antibiotic resistance of Vibrio parahaemolyticus and Vibrio vulnificus in various countries:a review. Food Microbiol. 2016;57:128–134.
50. Aslam S, Hamill RJ, Musher DM. Treatment of Clostridium difficile-associated disease:old therapies and new strategies. Lancet Infect Dis. 2005;5(9):549–557.
51. Kwon JH, Olsen MA, Dubberke ER. The morbidity, mortality, and costs associated with Clostridium difficile infection. Infect Dis Clin North Am. 2015;29(1):123–134.
52. Perfeito L, Fernandes L, Mota C, et al. Adaptive mutations in bacteria:high rate and small effects. Science. 2007;317(5839):813–815.
53. Scott L. Fidaxomicin:a review of its use in patients with Clostridium difficile infection. Drugs. 2013;73(15):1733–1747.
54. Almeida R, Gerbaba T, Petrof EO. Recurrent Clostridium difficile infection and the microbiome. J Gastroenterol. 2016;51(1):1–10.
55. Freeman J, Vernon J, Morris K, et al. Pan-European longitudinal surveillance of antibiotic resistance among prevalent Clostridium difficile ribotypes. Clin Microbiol Infect. 2015;21(3):248.e249-248.e216.
56. Shah D, Dang M-D, Hasbun R, et al. Clostridium difficile infection:update on emerging antibiotic treatment options and antibiotic resistance. Expert Rev Anti Infect Ther. 2010;8(5):555–564.
57. Ramesh V, Fralick JA, Rolfe RD. Prevention of Clostridium difficile-induced ileocecitis with bacteriophage. Anaerobe. 1999;5(2):69–78.
58. Hargreaves KR, Clokie MRJ. Clostridium difficile phages:still difficult? Front Microbiol. 2014;5(154).
59. Rajkumari N, John NV, Mathur P, et al. Antimicrobial resistance in Pseudomonas sp. causing infections in Trauma patients:a 6 year experience from a South Asian Country. J Glob Infect Dis. 2014;6(4):182–185.
60. Hirsch EB, Tam VH. Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes. Expert Rev Pharmacoecon Outcomes Res. 2010;10(4):441–451.
61. Potron A, Poirel L, Nordmann P. Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii:mechanisms and epidemiology. Int J Antimicrob Agents. 2015;45(6):568–585.
62. Boukadida J, de Montalembert M, Gaillard JL, et al. Outbreak of gut colonization by Pseudomonas aeruginosa in immunocompromised children undergoing total digestive decontamination:analysis by pulsed-field electrophoresis. J Clin Microbiol. 1991;29(9):2068–2071.
63. Doershuk CF, Stern RC. Spontaneous bacterial peritonitis in cystic fibrosis. Gut. 1994;35(5):709–711.
64. Manson WL, Coenen JMFH, Klasen HJ, et al. Intestinal bacterial translocation in experimentally burned mice with wounds colonized by pseudomonas aeruginosa. J Trauma Injury Infect Crit Care. 1992;33(5):654–658.
65. Pires DP, Vilas Boas D, Sillankorva S, et al. Phage therapy:a step forward in the treatment of Pseudomonas aeruginosa infections. J Virol. 2015;89(15):7449–7456.
66. Międzybrodzki R, Borysowski J, Weber-Dąbrowska B, et al. Chapter 3, Clinical aspects of phage therapy. In:Małgorzata Ł, Wacław S, editors. Advances in virus research. San Diego:Elsevier Academic Press Inc; 2012(83). p. 73–121.
67. Wright A, Hawkins CH, Änggård EE, et al. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin Otolaryngol. 2009;34(4):349–357.
68. Silva C, Calva E, Maloy S. One health and food-borne disease:Salmonella transmission between humans, animals, and plants. Microbiol Spectr. 2014;2(1):OH-0020-2013.
69. Hohmann EL. Nontyphoidal salmonellosis. Clin Infect Dis. 2001;32(2):263–269.
70. Bhan MK, Bahl R, Bhatnagar S. Typhoid and paratyphoid fever. Lancet. 2005;366(9487):749–762.
71. Chiu C-H, Su L-H CC. Salmonella enterica serotype Choleraesuis:epidemiology, pathogenesis, clinical disease, and treatment. Clin Microbiol Rev. 2004;17(2):311–322.
72. Álvarez-Ordóñez A, Begley M, Prieto M, et al. Salmonella spp. survival strategies within the host gastrointestinal tract. Microbiology. 2011;157(12):3268–3281.
73. Behnsen J, Perez-Lopez A, Nuccio SP, et al. Exploiting host immunity:the Salmonella paradigm. Trends Immunol. 2015;36(2):112–120.
74. Ruby T, McLaughlin L, Gopinath S, et al. Salmonella’s long-term relationship with its host. FEMS Microbiol Rev. 2012;36(3):600–615.
75. Trong TA, Nicholas AF, Melita AG, et al. Global burden of invasive nontyphoidal Salmonella disease, 2010. Emerging Infect Dis Journal. 2015;21(6):941.
76. Crump JA, Sjölund-Karlsson M, Gordon MA, et al. Epidemiology, clinical presentation, laboratory diagnosis, antimicrobial resistance, and antimicrobial management of invasive Salmonella infections. Clin Microbiol Rev. 2015;28(4):901–937.
77. Threlfall EJ. Antimicrobial drug resistance in Salmonella:problems and perspectives in food- and water-borne infections. FEMS Microbiol Rev. 2002;26(2):141–148.
78. Folster JP, Campbell D, Grass J, et al. Identification and characterization of multidrug-resistant Salmonella enterica serotype albert isolates in the United States. Antimicrob Agents Chemother. 2015;59(5):2774–2779.
79. Wall SK, Zhang JY, Rostagno MH, et al. Phage therapy to reduce preprocessing Salmonella infections in market-weight swine. Appl Environ Microbiol. 2010;76(1):48–53.
80. Gebru E, Lee JS, Son JC, et al. Effect of probiotic-, bacteriophage-, or organic acid-supplemented feeds or fermented soybean meal on the growth performance, acute-phase response, and bacterial shedding of grower pigs challenged with Salmonella enterica serotype Typhimurium. J Anim Sci. 2010;88(12):3880–3886.
81. Albino LAA, Rostagno MH, Hungaro HM, et al. Isolation, characterization, and application of bacteriophages for Salmonella spp. biocontrol in pigs. Foodborne Pathog Dis. 2014;11(8):602–609.
82. Callaway TR, Edrington TS, Brabban A, et al. Evaluation of phage treatment as a strategy to reduce Salmonella populations in growing swine. Foodborne Pathog Dis. 2011;8(2):261–266.
83. Fiorentin L, Vieira ND, Barioni W. Oral treatment with bacteriophages reduces the concentration of Salmonella Enteritidis PT4 in caecal contents of broilers. Avian Pathol. 2005;34(3):258–263.
84. Andreatti RLF, Higgins JP, Higgins SE, et al. Ability of bacteriophages isolated from different sources to reduce Salmonella enterica serovar enteritidis in vitro and in vivo. Poult Sci. 2007;86(9):1904–1909.
85. Kumar N, David MZ, Boyle-Vavra S, et al. High Staphylococcus aureus colonization prevalence among patients with skin and soft tissue infections and controls in an urban emergency department. J Clin Microbiol. 2015;53(3):810–815.
86. Kikuchi K, Takahashi N, Piao CC, et al. Molecular epidemiology of methicillin-resistant Staphylococcus aureus strains causing neonatal toxic shock syndrome-like exanthematous disease in neonatal and perinatal wards. J Clin Microbiol. 2003;41(7):3001–3006.
87. Boyce JM, Havill NL. Nosocomial antibiotic-associated diarrhea associated with enterotoxin-producing strains of methicillin-resistant Staphylococcus aureus. Am J Gastroenterol. 2005;100(8):1828–1834.
88. Lis DO, Pacha JZ, Idzik D. Methicillin resistance of airborne coagulase-negative staphylococci in homes of persons having contact with a hospital environment. Am J Infect Control. 2009;37(3):177–182.
89. O’Flaherty S, Coffey A, Meaney W, et al. The recombinant phage lysin LysK has a broad spectrum of lytic activity against clinically relevant Staphylococci, including methicillin-resistant Staphylococcus aureus. J Bacteriol. 2005;187(20):7161–7164.
90. Acton DS, Mjt P-S, van Wamel W, et al. Intestinal carriage of Staphylococcus aureus:how does its frequency compare with that of nasal carriage and what is its clinical impact? Eur J Clin Microbiol Infect Dis. 2009;28(2):115–127.
91. Wills QF, Kerrigan C, Soothill JS. Experimental bacteriophage protection against Staphylococcus aureus abscesses in a rabbit model. Antimicrob Agents Chemother. 2005;49(3):1220–1221.
92. Capparelli R, Parlato M, Borriello G, et al. Experimental phage therapy against Staphylococcus aureus in mice. Antimicrob Agents Chemother. 2007;51(8):2765–2773.
93. Kaźmierczak Z, Górski A, Dąbrowska K. Facing antibiotic resistance:Staphylococcus aureus phages as a medical tool. Viruses. 2014;6(7):2551–2570.
94. Vandersteegen K, Kropinski AM, Nash JHE, et al. Romulus and Remus, two phage isolates representing a distinct clade within the Twortlikevirus genus, display suitable properties for phage therapy applications. J Virol. 2013;87(6):3237–3247.
95. Vandersteegen K, Mattheus W, Ceyssens P-J, et al. Microbiological and molecular assessment of bacteriophage ISP for the control of Staphylococcus aureus. Plos One. 2011;6(9):e24418.
96. Leszczyński P, Weber-Dabrowska B, Kohutnicka M, et al. Successful eradication of methicillin-resistant Staphylococcus aureus (MRSA) intestinal carrier status in a healthcare worker - case report. Folia Microbiol (Praha). 2006;51(3):236–238.
97. Lusiak-Szelachowska M, Zaczek M, Weber-Dabrowska B, et al. Phage neutralization by Sera of patients receiving phage therapy. Viral Immunol. 2014;27(6):295–304.
98. Borysowski J, Górski A. Is phage therapy acceptable in the immunocompromised host? Int J Infect Dis. 2008;12(5):466–471.
99. Francino MP. Antibiotics and the human gut microbiome:dysbioses and accumulation of resistances. Front Microbiol. 2015;6:1543.
100. Abdulamir AS, Jassim SAA, Bakar FA. Novel approach of using a cocktail of designed bacteriophages against gut pathogenic E. coli for bacterial load biocontrol. Ann Clin Microbiol Antimicrob. 2014;13(39).
101. Kang H-W, Kim J-W, Jung T-S, et al. wksl3, a new biocontrol agent for Salmonella enterica Serovars Enteritidis and Typhimurium in foods:characterization, application, sequence analysis, and oral acute toxicity study. Appl Environ Microbiol. 2013;79(6):1956–1968.
102. Denou E, Bruttin A, Barretto C, et al. T4 phages against Escherichia coli diarrhea:potential and problems. Virology. 2009;388(1):21–30.
103. Bruttin A, Brussow H. Human volunteers receiving Escherichia coli phage T4 orally:a safety test of phage therapy. Antimicrob Agents Chemother. 2005;49(7):2874–2878.
104. Sarker SA, McCallin S, Barretto C, et al. Oral T4-like phage cocktail application to healthy adult volunteers from Bangladesh. Virology. 2012;434(2):222–232.
105. McCallin S, Sarker S, Barrett C, et al. Safety analysis of a Russian phage cocktail:from metagenomic analysis to oral application in healthy human subjects. Virology. 2013;443(2):187–196.
106. Gorski A, Miedzybrodzki R, Borysowski J, et al. Phage as a modulator of immune responses:practical implications for phage therapy. In:Lobocka M, Szybalski WT, editors. Advances in virus research, Vol 83:bacteriophages, Pt B. San Diego:Elsevier Academic Press Inc; 2012. p. 41–71.
107. Miernikiewicz P, Dabrowska K, Piotrowicz A, et al. T4 phage and its head surface proteins do not stimulate inflammatory mediator production. PLoS One. 2013;8(8):e71036.
108. Miernikiewicz P, Dabrowska K, Piotrowicz A, et al. T4 phages head proteins do not induce production of reactive oxygen species by granulocytes. Immunology. 2012;137:203–203.
109. Park K, Cha KE, Myung H. Observation of inflammatory responses in mice orally fed with bacteriophage T7. J Appl Microbiol. 2014;117(3):627–633.
110. Weber-Dabrowska B, Zimecki M, Mulczyk M, et al. Effect of phage therapy on the turnover and function of peripheral neutrophils. FEMS Immunol Med Microbiol. 2002;34(2):135–138.
111. Chibani-Chennoufi S, Sidoti J, Bruttin A, et al. In vitro and in vivo bacteriolytic activities of Escherichia coli phages:implications for phage therapy. Antimicrob Agents Chemother. 2004;48(7):2558–2569.
112. Tennant SM, Hartland EL, Phumoonna T, et al. Influence of gastric acid on susceptibility to infection with ingested bacterial pathogens. Infect Immun. 2008;76(2):639–645.
113. Cook GC. Infective gastroenteritis and its relationship to reduced gastric acidity. Scand J Gastroenterol. 1985;20(sup111):17–22.
114. Chohiska-Pulit A, Mitula P, Sliwka P, et al. Bacteriophage encapsulation:trends and potential applications. Trends Food Sci Technol. 2015;45(2):212–221.
115. Zhenxing T, Xiaoqing H, Shailja B, et al. Whey protein improves survival and release characteristics of bacteriophage Felix O1 encapsulated in alginate microspheres. Food Res Int. 2013;52(2):460–466.
116. Tang Z, Huang X, Sabour PM, et al. Preparation and characterization of dry powder bacteriophage K for intestinal delivery through oral administration. Lwt-Food Sci Technol. 2015;60(1):263–270.
117. Dini C, Islan GA, Castro GR. Characterization and stability analysis of biopolymeric matrices designed for phage-controlled release. Appl Biochem Biotechnol. 2014;174(6):2031–2047.
118. Stephen TA, Cameron T-A. Phage therapy pharmacology. Curr Pharm Biotechnol. 2010;11(1):28–47.
119. Smith GP, Petrenko VA. Phage display. Chem Rev. 1997;97(2):391–410.
120. Nicastro J, Sheldon K, Slavcev RA. Bacteriophage lambda display systems:developments and applications. Appl Microbiol Biotechnol. 2014;98(7):2853–2866.
121. Jo A, Ding T, Ahn J. Synergistic antimicrobial activity of bacteriophages and antibiotics against Staphylococcus aureus. Food Sci Biotechnol. 2016;25(3):935–940.
122. Torres-Barceló C, Hochberg ME. Evolutionary rationale for phages as complements of antibiotics. Trends Microbiol. 2016;24(4):249–256.
123. Kamal F, Dennis JJ. Burkholderia cepacia complex Phage-Antibiotic Synergy (PAS):antibiotics stimulate lytic phage activity. Appl Environ Microbiol. 2015;81(3):1132–1138.
124. Cao J, Sun Y-Q, Berglindh T, et al. Helicobacter pylori-antigen-binding fragments expressed on the filamentous M13 phage prevent bacterial growth. Biochimica Biophysica Acta (BBA). 2000;1474(1):107–113.
125. Jun SY, Jung GM, Yoon SJ, et al. Antibacterial properties of a pre-formulated recombinant phage endolysin, SAL-1. Int J Antimicrob Agents. 2013;41(2):156–161.
126. Lood R, Winer BY, Pelzek AJ, et al. Novel phage lysin capable of killing the multidrug-resistant gram-negative bacterium Acinetobacter baumannii in a mouse bacteremia model. Antimicrob Agents Chemother. 2015;59(4):1983–1991.
127. Nelson DC, Schmelcher M, Rodriguez-Rubio L, et al. Endolysins as antimicrobials. Adv Virus Res. 2012;83:299–365.
128. Kittler S, Fischer S, Abdulmawjood A, et al. Effect of bacteriophage application on Campylobacter jejuni loads in commercial broiler flocks. Appl Environ Microbiol. 2013;79(23):7525–7533.
129. Carvalho CM, Gannon BW, Halfhide DE, et al. The in vivo efficacy of two administration routes of a phage cocktail to reduce numbers of Campylobacter coli and Campylobacter jejuni in chickens. BMC Microbiol. 2010;10(232):1.